Biotechnology Value Fund, L.P. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotechnology Value Fund, L.P.

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: mopgcw	1/10/2006 6:35:08 AM
	Read Replies (1) of 4974

Progenics Pharmaceuticals Files 4M-Share Shelf DOW JONES NEWSWIRES January 9, 2006 3:39 p.m. WASHINGTON -- Progenics Pharmaceuticals Inc. (PGNX) on Monday registered to sell from time to time up to 4 million common shares, according to a Form S-3 filed with the Securities and Exchange Commission. The biopharmaceutical company said it intends to use the net proceeds to fund clinical trials for product candidates, other research and development activities, and in-licensing of technology and establishment of research and development collaborations. The company may also use the proceeds for working capital and general corporate purposes, including potential acquisitions of technology or companies in complementary fields, according the filing. No underwriters were listed in the filing. Shares of the company recently traded at $30.39 each, up $1.14.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next